- Home
- HES vs ALNY Comparison
HES vs ALNY Comparison
Compare HES & ALNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HES
- ALNY
- Stock Information
- Founded
- HES 1920
- ALNY 2002
- Country
- HES United States
- ALNY United States
- Employees
- HES N/A
- ALNY N/A
- Industry
- HES Integrated oil Companies
- ALNY Biotechnology: Pharmaceutical Preparations
- Sector
- HES Energy
- ALNY Health Care
- Exchange
- HES Nasdaq
- ALNY Nasdaq
- Market Cap
- HES 41.4B
- ALNY 35.0B
- IPO Year
- HES N/A
- ALNY 2004
- Fundamental
- Price
- HES $130.64
- ALNY $234.56
- Analyst Decision
- HES Buy
- ALNY Strong Buy
- Analyst Count
- HES 10
- ALNY 24
- Target Price
- HES $166.86
- ALNY $322.39
- AVG Volume (30 Days)
- HES 2.3M
- ALNY 1.3M
- Earning Date
- HES 04-30-2025
- ALNY 05-01-2025
- Dividend Yield
- HES 1.53%
- ALNY N/A
- EPS Growth
- HES 100.00
- ALNY N/A
- EPS
- HES 8.98
- ALNY N/A
- Revenue
- HES $12,662,000,000.00
- ALNY $2,248,243,000.00
- Revenue This Year
- HES N/A
- ALNY $31.17
- Revenue Next Year
- HES $16.57
- ALNY $24.99
- P/E Ratio
- HES $14.55
- ALNY N/A
- Revenue Growth
- HES 22.99
- ALNY 22.97
- 52 Week Low
- HES $123.79
- ALNY $141.98
- 52 Week High
- HES $163.98
- ALNY $304.39
- Technical
- Relative Strength Index (RSI)
- HES 38.27
- ALNY 44.35
- Support Level
- HES $124.34
- ALNY $225.84
- Resistance Level
- HES $131.63
- ALNY $242.15
- Average True Range (ATR)
- HES 6.40
- ALNY 17.21
- MACD
- HES -1.95
- ALNY -2.15
- Stochastic Oscillator
- HES 16.87
- ALNY 42.35
About HES Hess Corporation
Hess is an independent oil and gas producer with key assets in the Bakken Shale, Guyana, the Gulf of Mexico, and Southeast Asia. At the end of 2023, the company reported net proved reserves of 1.4 billion barrels of oil equivalent. Net production averaged 391 thousand barrels of oil equivalent per day in 2023, at a ratio of 74% oil and natural gas liquids and 26% natural gas.
About ALNY Alnylam Pharmaceuticals Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.